Compare Pfizer Inc (PFE) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Symbotic Inc — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Symbotic Inc trades at $42.52 (market cap $5.45B). The key difference: Pfizer Inc is far larger — about 26.1× Symbotic Inc's market cap, and Pfizer Inc pays a 6.9% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| PFE | SYM | |
|---|---|---|
Market Cap | $142.14B | $5.45B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $28.56 | $87.30 |
52-Week Low | $23.29 | $38.57 |
Enterprise Value | $192.80B | $3.44B |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
SYM trades at $40.83, down 1.02% with bearish technical signals despite recent earnings beats. The company shows revenue growth potential with $2.25B in 2025 revenue and improving margins, though net income remains negative. Analyst consensus is bullish with a $57.50 price target, while technical indicators show oversold conditions with RSI at 29.43. Recent news highlights Symbotic's positioning in warehouse robotics and AI automation.
The stock presents a growth opportunity in the expanding warehouse automation market, supported by strong analyst buy ratings and improving financial trends. Key risks include continued negative profitability, high valuation multiples, and competitive pressures in the robotics sector. Near-term catalysts include Q2 2026 earnings and execution on the company's $1.1B projected net cash flow for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
